Abstract: TH-PO0503
Urinary V-Set Ig Domain-Containing Protein 4 (VSIG4) in IgAN: Correlation with Clinicopathological Features and Predictive Significance for Kidney Prognosis
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - IgAN
October 22, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Tang, Lingqi, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
- Ma, Rui, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
- Li, Xiaohua, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
- Yang, Zhenhua, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
- Pan, Ling, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Background
IgAN is the most common cause of chronic renal failure. This study aimed to explore urinary VSIG4 as a non-invasive predictive biomarker in IgAN patients.
Methods
This single-center prospective cohort study enrolled IgAN patients diagnosed at The First Affiliated Hospital of Guangxi Medical University from 2020 to 2025 along with paired healthy volunteers. Patients in the IgAN group were followed for at least 6 months. Baseline morning urinary VSIG4 levels were measured using ELISA and normalized to urinary creatinine. The endpoint was defined as a 40% decline in eGFR from baseline or progression to ESRD.
Results
A total of 120 patients with primary IgAN were included. 55 healthy volunteers were enrolled. Urinary VSIG4 level in the IgAN group were significantly higher than those in the healthy control group (P<0.001). Urinary VSIG4 was negatively correlated with eGFR and hemoglobin, and positively correlated with 24h-UTP and Oxford pathology classification scores. Baseline declined renal function correlated with higher urinary VSIG4 levels in IgAN patients (P = 0.022). ROC analysis for VSIG4 to distinguish IgAN patients from healthy subjects showed an AUC of 0.852 (P<0.0001), with a sensitivity of 62.5% and a specificity of 94.5%. For predicting adverse renal outcomes in IgAN, the AUC of urinary VSIG4 was 0.773 (P<0.001), with a sensitivity of 81.8%, a specificity of 72.4%, and an optimal cut-off value of 21.9 ng/mg. Based on this cut-off, IgAN patients were divided into low and high urinary VSIG4 groups.Kaplan–Meier curve analysis indicated that the incidence of adverse renal outcomes was significantly higher in the high urinary VSIG4 group (P<0.001). Three hierarchically adjusted models were constructed for multivariate Cox regression analysis. Model 1 was adjusted for clinical factors including age, sex, baseline 24h-UTP, baseline eGFR, MAP and microscopic hematuria. Model 2 was further adjusted for MEST-C score based on of Model 1. Model 3 was additionally adjusted for medication factors. The results indicated that high urinary VSIG4 level was an independent risk factor for adverse renal outcomes (Model 1 HR=4.19,P=0.017; Model 2 HR=5.84, P=0.006; Model 3 HR=5.46, P=0.008).
Conclusion
VSIG4 holds promising clinical value as a biomarker in early predicting the renal progression of IgAN.
Funding
- Government Support – Non-U.S.